Noven To Announce 2002 Financial Results On March 3

Public Invited to Listen to Earnings Conference Call Via Internet

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced its 2002 fourth quarter and year end earnings release date.

On March 3, before the market opens, Noven is scheduled to issue a press release announcing its financial results for the quarter and year ended December 31, 2002. Beginning at 10:00 a.m. Eastern Time the same day, a telephone conference among management and analysts will be broadcast live via the Internet at www.noven.com, and a rebroadcast will be accessible at the same site. A taped replay of the call will be available by telephone beginning the morning of March 3 at 11:00 a.m. through noon on March 6 by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering (the conference ID# 58491 and the access code 1628.)

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. For additional information on Noven, visit www.noven.com.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women’s health products company called Novogyne Pharmaceuticals. Noven’s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch® for ADHD, Noven is committed to becoming the world’s premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information, visit Noven’s website at www.noven.com.

Duragesic® is a registered trademark of Janssen Pharmaceutica, L.P.

This release contains forward-looking information related to the business of Noven that can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "could", "potential", "would", "should" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven’s most recent filings with the Securities and Exchange Commission and those specified herein, including the risk that: we may fail to develop new products or establish new strategic collaborations, either of which would significantly limit our ability to leverage our technology, diversify our prospects and execute on our growth strategy; product development is inherently risky, and any project, including our dextroamphetamine or fentanyl patches, could fail at any time or be delayed indefinitely; the timing of ANDA approval for our fentanyl patch could be affected by any number of issues that are beyond our control, including patent strategies by the innovator and strategies by generic competitors that could result in exclusivity; with several companies expected to offer a generic version of Duragesic, product pricing and other competitive factors may substantially diminish the market opportunity available to Noven; the Shire transaction may not close; and MethyPatch may not be approved or, if approved, it may not be successfully commercialized by Shire due to competitive market conditions or other factors, including physician/patient preferences for other ADHD therapies.

Contact:
Stefaney Caro
Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916